USP comments to FDA on Docket No. FDA-2022-N-0236 for “Prioritizing the Addition of Maximum Daily Exposure Information and Removing Dosage Form Information from the Inactive Ingredient Database. Comments were submitted in 2022.
USP-Comments-on-FDA-IID-Docket.pdf
(164.9 KB)
Public Policy